EHA24: Updated Results on the AZD-0486 Trial for Treating Relapsed Refractory Follicular Lymphoma

Ryan Jacobs, the Director of Lymphoma at Levine Cancer Institute, presents in this MEDtalk an update on his research from the EHA 2023 meeting on AZD-0486, a novel CD19/CD3 T-cell engager used in treating relapsed refractory follicular lymphoma. The update includes patient responses and tolerability information, highlighting findings such as high overall response rates, complete remission rates, and low toxicity with the double step-up dosing method.